Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Hugo Raul Castro-Salguero"'
Autor:
Zev A. Wainberg, Kohei Shitara, Eric Van Cutsem, Lucjan Wyrwicz, Keun Wook Lee, Iveta Kudaba, Marcelo Garrido, Hyun Cheol Cheol Chung, Jeeyun Lee, Hugo Raul Castro-Salguero, Wasat Mansoor, Maria Ignez Braghiroli, Nina Karaseva, Eray Goekkurt, Hironaga Satake, Joseph Chao, Uma Kher, Sukrut Shah, Pooja Bhagia, Josep Tabernero
Publikováno v:
Journal of Clinical Oncology. 40:243-243
243 Background: KEYNOTE-062 (NCT02494583) is a global phase 3 study of pembrolizumab (pembro) as monotherapy and in combination with chemotherapy (chemo) versus chemo as first-line therapy for PD-L1–positive (combined positive score [CPS] ≥1) adv
Autor:
Soonmo Peter Kang, Marcelo Garrido, Hyun Cheol Chung, Lucjan Wyrwicz, Iveta Kudaba, Sukrut Shah, Zev A. Wainberg, Wasat Mansoor, Kohei Shitara, Charles S. Fuchs, Joseph Chao, Uma Kher, Keun Wook Lee, Yung-Jue Bang, Eray Goekkurt, Eric Van Cutsem, Hugo Raul Castro Salguero, Maria Ignez Braghiroli, Josep Tabernero
Publikováno v:
Journal of Clinical Oncology. 37:LBA4007-LBA4007
LBA4007 Background: KEYNOTE062 (NCT02494583) was a randomized, active controlled study of 1L P or P+C vs C in pts with PD-L1 combined positive score ≥1 (CPS ≥1), HER2-negative, advanced GC. Methods: Eligible pts were randomized 1:1:1 to P 200 mg
Autor:
Priya Rastogi, Andreas Schneeweiss, Sibylle Loibl, Michael Untch, Hervé Bonnefoi, Ljiljana Stamatovic, Pierfranco Conte, Charles E. Geyer, Andrés Redondo, Hugo Raul Castro Salguero, Véronique D'Hondt, Eleftherios P. Mamounas, Gunter von Minckwitz, Max S. Mano, Peter Trask, Chunyan Song, Hans Holger Fischer, Tanya A. Wahl, Steven Blotner, Chiun-Sheng Huang
Publikováno v:
Journal of Clinical Oncology. 37:513-513
513 Background: The phase 3 KATHERINE (NCT01772472) study, met its primary endpoint by demonstrating significantly improved invasive disease-free survival with adjuvant T-DM1 compared to H in pts with residual invasive disease after neoadjuvant chemo
Autor:
Mario Guardia, Jenny Lissette Castro, Noe V. Castro, Jorge Umanzor, Gerardo Antonio Umanzor Funez, Hugo Raul Castro Salguero, Ludwing Alexander Bacon Fonseca, Allan Ramos-Esquivel, Allan Barillas, Angela Margarita Cabreja, Finlander Rosales, Francisco Alvarado, Pier Angelo Ramos, Luis Garcia-Aceituno, Yong Pain Loo
Publikováno v:
Journal of Clinical Oncology. 37:e15126-e15126
e15126 Background: Metastatic colorectal cancer (MCRC) survival has been improved in the last decade due to the identification of predictive and prognostic factors such as RAS gene status and also by the addition of targeted therapies to chemotherapy